Triple therapy reduces exacerbations & improves control in m
A Study was conducted to systematically synthesize the outcomes and adverse events associated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma. 20 RCTs using 3 LAMA types that enrolled 11894 children and adults were included. The benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABAs) for moderate to severe asthma remains unclear.

--High-certainty evidence showed that triple therapy vs dual therapy was significantly associated with a reduction in severe exacerbation risk.

--There were no significant differences in asthma-related quality of life or mortality between dual and triple therapy.

--Triple therapy was significantly associated with increased dry mouth and dysphonia, but treatment-related and serious adverse events were not significantly different between groups.

Conclusively, triple therapy was substantially linked with fewer severe exacerbations and small improvements in asthma management among children (ages 6 to 18 years) and adults with moderate to severe asthma compared to double therapy without substantial differences in quality of life or mortality.